Dr. David Winter Joins Human BioSystems Advisory Board.

PALO ALTO, Calif. -- Human BioSystems (OTCBB:HBSC) announced today that David Winter, MD has been appointed to the Company's advisory board.

Dr. Winter began his career as a research scientist for NIH and was later appointed the Director of Life Sciences for NASA. In this position he directed all the medical, biological and biomedical-engineering activities for the US space program.

In the late 1970's Dr. Winter directed his career into the private industry sector where he focused his efforts in pharmaceutical/medical companies.

His experience includes: President and COO of GenPharm International, President and COO of SangStat Medical Corp. and most recently President and COO of Human Organ Sciences.

Dr. Winter is an experienced physician with a strong background in managing the complex clinical development and approval process. He previously served as President of the Sandoz Research Institute and as Vice President of Clinical Research and Development for Sandoz Pharmaceuticals. At Sandoz, he led the development, registration and approval of cyclosporine as well as six other major compounds. He earned his MD at the Washington University School of Medicine in St. Louis.

Currently Dr. Winter is President and CEO of TriMed Research, Inc., a joint venture of the University of Nebraska Medical Center, UNeMed Corporation and Tridelta Development, Ltd. that is focused on the commercialization of the MAA protein.

"Dr. Winter will provide invaluable advice and counsel on every aspect of our company's direction and growth," Harry Masuda, HBS President and CEO said. "His impressive medical and business background, vast knowledge of our specific industry and his worldwide high level contacts will be of great importance for our future success."

"I look forward to utilizing my experience and resources in helping Human BioSystems achieve success with its exciting technologies," Dr. Winter said.

In other news, Human BioSystems, announced that it has signed an agreement with Langley Park Investments Plc for the purchase by the investment company of US $930,999 of Human BioSystems common stock in exchange for shares of the investment company.

The investment firm is a newly formed London-based company whose shares have been admitted to trading on the London stock exchange as an investment trust. The investment company has been established specifically to invest in US micro cap companies with long term growth potential.

The investment company has entered into a "lock-up" agreement with Human BioSystems pursuant to which it has agreed not to trade the Human BioSystems shares it will receive as a result of this transaction for a period of two years from the closing date. In full payment for the shares of Human BioSystems, the investment company will issue to Human BioSystems USD $930,000 equivalent of its shares at a price per share valued at One Pound Sterling.

Fifty percent of the investment company's shares will be held in escrow for two years following their issuance and in the event the per share market price of Human BioSystems' common stock at such time is less than the per share value of Human BioSystems' stock at the time of the closing, the investment company shall be entitled to receive out of escrow a percentage of the shares equal to the percentage of such decline. The remaining shares held in escrow shall be released to Human BioSystems at such time.

Human BioSystems is headquartered in Palo Alto, California.

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from future research and testing, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the technology we have acquired, failure of any such products to compete effectively with existing products, failure to develop a cost effective commercial manufacturing method, the ability of the Company to fund additional studies and product development and other factors discussed in filings made by the Company with the Securities and Exchange Commission.